Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

KPTI Karyopharm Therapeutics Inc.
$6.58 4.68% +0.30
Notify me if price changes either direction
Interactive Brokers Logotype

Buy KPTI stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 115.5M
Enterprise value 331.6M
Trailing PE -0.6962962962963
Forward PE -1.3258883
PEG Ratio 0.33944444444444
Enterprise to EBITDA -3.195
Enterprise to revenue 2.327
Price to book MRQ -0.21184893299363
Price to sales TTM 0.8388842

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 142.5M
EBITDA -103786000
Diluted EPS TTM -14.7
Total Cash (MRQ) 45.9M
Current ratio (MRQ) 1.03
Operating Cash Flow (TTM) -89351000

KPTI trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent KPTI News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.